MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Immatics N.V. (NASDAQ: IMTX)*
Organization & Developments: Immatics
Parents
Immatics N.V. (NASDAQ: IMTX)*
Children
*Immatics’ gamma delta T cell-derived, allogeneic adoptive cell therapy platform, called ACTallo.
*Pipeline of Adoptive Cell Therapies and TCR Bispecifics
*The companies will develop multiple allogeneic, or so-called off-the-shelf, TCR-T and CAR-T programs
2022: GSK severs Immatics partnership in T-cell retreat that claimed Lyell last month
2022: One protein, many cancers: Immatics finds a multi-tumor target for adoptive T-cell therapies
2022: UPDATE: Bristol Myers triples-down on Immatics, bringing deal to $4.2B total biobucks. Why not just buy it?
2023: Immatics' solid tumor data fan PRAME flame, sending stock soaring
2024: Immatics: Big Pharma Partners, Intriguing Catalysts Make Buy Case
2024: Immatics: Pioneering TCR Therapies In The Fight Against Cancer
2025: As the investor pendulum swings away from cell therapy, Immatics CEO focuses on raising the bar
2025: Immatics N.V.: Considering More Engineered T Cells For Cancer
2025: Immatics: Taking Off On A PRAME Rocketship
Jumps
Finance & Acquisitions: Immatics
Key People: Immatics